However, Dimopoulos et al. used CRBN IHC staining in FFPE bone marrow samples of 23 MM patients and found no correlation between the CRBN protein level and the sensitivity or intrinsic resistance to lenalidomide-based therapy [19]. The gene discussed is CRBN; the disease is Miyoshi myopathy.